Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who were given a combination of two blood-thinning medicines — aspirin and one of three specific medicines (ticagrelor, prasugrel, or clopidogrel) — either when their heart attack was diagnosed or at the latest during their emergency stenting procedure.
- People who had at least one blocked heart artery treated with a successful emergency stenting procedure, where a specific type of stent (called the Abluminus NP stent) was placed, and the blockage was largely cleared.
- People who are willing to take part and are able to understand, read, and sign a consent form.
Who may not be able to join:
- People with a known allergy or bad reaction to aspirin, ticagrelor, prasugrel, or sirolimus.
- People who would not be able to take the two-medicine blood-thinning combination for at least 6 months.
- People who were already taking this two-medicine blood-thinning combination before the heart attack, due to a heart stenting procedure done within the past 6 months, or a previous heart attack treated within the past 12 months.
- People who were already taking long-term blood-thinning tablets (anticoagulants) at the time of their heart attack.
- People who experienced a serious physical complication directly caused by the heart attack.
- People whose heart attack was caused by a previously placed stent becoming blocked.
- People who have planned non-heart surgery that cannot be delayed for at least 6 months.
- People who are already taking part in, or planning to join, another clinical trial that involves a medical procedure or treatment.
- People with a life expectancy of less than one year.
- People who are pregnant.
- People who are unwilling or unable — for any reason, including physical or cognitive difficulties — to follow the study's requirements, take medicines as directed, or attend scheduled visits.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Juan F. Iglesias, MD, University Hospital, Geneva
Phone: +41795530516
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of major adverse cardiac and cerebrovascular events (MACCE); Rate of BARC class 3 or 5 major bleeding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.